PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
EBIT growth similar to CRVO's 100.00%. Walter Schloss might infer both firms share similar operational efficiencies.
-121.69%
Negative operating income growth while CRVO is at 26.76%. Joel Greenblatt would press for urgent turnaround measures.
-139.60%
Negative net income growth while CRVO stands at 27.02%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-131.82%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-131.82%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-31.70%
Negative OCF growth while CRVO is at 51.63%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-31.70%
Negative FCF growth while CRVO is at 51.63%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while CRVO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
95.37%
10Y OCF/share CAGR in line with CRVO's 99.91%. Walter Schloss would see both as similarly efficient over the decade.
75.95%
5Y OCF/share CAGR at 75-90% of CRVO's 94.12%. Bill Ackman would push for operational improvements to match competitor’s mid-term gains.
7.00%
3Y OCF/share CAGR under 50% of CRVO's 87.14%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
81.58%
Net income/share CAGR at 75-90% of CRVO's 99.91%. Bill Ackman would press for strategic moves to boost long-term earnings.
47.75%
5Y net income/share CAGR at 50-75% of CRVO's 89.89%. Martin Whitman might see a shortfall in operational efficiency or brand power.
-122.09%
Negative 3Y CAGR while CRVO is 83.12%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-94.45%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
58.16%
Positive 5Y equity/share CAGR while CRVO is negative. John Neff might see a clear edge in retaining earnings or managing capital better.
-73.50%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-21.56%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-8.90%
We’re deleveraging while CRVO stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
60.05%
We increase R&D while CRVO cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
231.77%
SG&A growth well above CRVO's 2.86%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.